Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Erlotinib | 19.9526 | uM | 9 | 156.25 | 92.36 | 182.00 | 144.75 | 1.2573 | 1.8475 |
| SK-BR-3 | Lapatinib | 0.031623 | uM | 9 | 156.25 | 92.36 | 100.00 | 144.75 | 0.6909 | 0.1304 |
| SK-BR-3 | Lapatinib | 0.0016596 | uM | 9 | 156.25 | 92.36 | 110.00 | 144.75 | 0.7599 | 0.3094 |
| SK-BR-3 | 17-AAG | 0.031623 | uM | 9 | 156.25 | 92.36 | 48.00 | 144.75 | 0.3316 | -0.6357 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 130.00 | 144.75 | 0.8981 | 0.6944 | |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 358.00 | 379.00 | 0.9446 | 0.8797 | |
| SK-BR-3 | Erlotinib | 0.01 | uM | 9 | 312.50 | 200.50 | 387.00 | 379.00 | 1.0211 | 1.0460 |
| SK-BR-3 | 17-AAG | 0.000302 | uM | 9 | 312.50 | 200.50 | 316.00 | 379.00 | 0.8338 | 0.6409 |
| SK-BR-3 | Erlotinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 456.00 | 379.00 | 1.2032 | 1.4461 |
| SK-BR-3 | Erlotinib | 1 | uM | 9 | 312.50 | 200.50 | 389.00 | 379.00 | 1.0264 | 1.0575 |
| SK-BR-3 | Lapatinib | 10 | uM | 9 | 312.50 | 200.50 | 105.00 | 379.00 | 0.2770 | -0.5055 |
| SK-BR-3 | Linsitinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 447.00 | 379.00 | 1.1794 | 1.3936 |
| SK-BR-3 | 17-AAG | 0.0001 | uM | 9 | 312.50 | 200.50 | 497.00 | 379.00 | 1.3113 | 1.6865 |
| SK-BR-3 | Erlotinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 467.00 | 379.00 | 1.2322 | 1.5104 |
| SK-BR-3 | Lapatinib | 1 | uM | 9 | 312.50 | 200.50 | 220.00 | 379.00 | 0.5805 | 0.1063 |
| SK-BR-3 | Linsitinib | 10 | uM | 9 | 312.50 | 200.50 | 298.00 | 379.00 | 0.7863 | 0.5394 |
| SK-BR-3 | Erlotinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 267.00 | 379.00 | 0.7045 | 0.3659 |
| SK-BR-3 | Erlotinib | 10 | uM | 9 | 312.50 | 200.50 | 195.00 | 379.00 | 0.5145 | -0.0298 |
| SK-BR-3 | Linsitinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 368.00 | 379.00 | 0.9710 | 0.9369 |
| SK-BR-3 | Linsitinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 506.00 | 379.00 | 1.3351 | 1.7395 |
| SK-BR-3 | 17-AAG | 0.01 | uM | 9 | 312.50 | 200.50 | 172.00 | 379.00 | 0.4538 | -0.1537 |
| SK-BR-3 | Lapatinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 140.00 | 379.00 | 0.3694 | -0.3236 |
| SK-BR-3 | 17-AAG | 0.001 | uM | 9 | 312.50 | 200.50 | 529.00 | 379.00 | 1.3958 | 1.8753 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 455.00 | 379.00 | 1.2005 | 1.4403 | |
| SK-BR-3 | 17-AAG | 0.0031623 | uM | 9 | 312.50 | 200.50 | 264.00 | 379.00 | 0.6966 | 0.3492 |